الفهرس 
the Outcome of cancerOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
Hepatocellular carcinoma(HCC)is the world’s fifth leading cause of cancer and a major health problem in Egypt. At best, liver transplantation and surgical excision are the only therapy choices. As a result, there is a pressing need to research and assess different chemopreventive and therapeutic techniques that could be useful in the treatment of liver cancer. This study aimed to explore anti-tumor properties and defensive role of diarylheptanoid in HCC induced mice by DAB and PB and followed by diarylheptanoid administration either alone or in combination with sorafenib. Biochemical parameters of liver function, oxidative stress markers, and antioxidative markers were measured. Furthermore, the effect of co-administration of diarylheptanoid and sorafenib on expression of genes (IL 6, IL10, caspase 8 MMP9, VEGF, p53) on tumor cells was evaluated by RT- PCR. The results revealed that the addition of diarylheptanoid and sorafenib induced antitumor responses. co-administration of diarylheptanoid and sorafenib restored the liver functions enzyme activities in serum. Moreover, diarylheptanoid administration and sorafenib reduced the hepatic levels of oxidative stress markers (MDA) and enhanced the antioxidant parameters (SOD). A significant (P≤0.05) downregulated expression of the IL 10,P53, and caspase 8 gene in the HCC mice, however, the MMP9, IL 6 and VEGF genes were upregulated in HCC group .There was improvement in the histological picture of hepatic tissue of treated groups with sorafenib and diarylhetanoid in comparison to HCC bearing positive control group.